Search

Alice T Epitropoulos,1,2 Sheraz M Daya,3 Cynthia Matossian,4 Alan G Kabat,5,6 Gretchen Blemker,5 Kristen Striffler,5 Laura Hendrix,5 Marian Macsai,5 Andrea Gibson5 1Ophthalmic Surgeons & Consultants of Ohio, the Eye Center of Columbus, Columbus, OH, USA; 2Department of Ophthalmology, the Ohio State University Wexner Medical Center, Columbus, OH, USA; 3Centre for Sight, London, UK; 4Matossian Eye Associates, Pennington, NJ, USA; 5Oyster Point Pharma, Inc, Princeton, NJ, USA; 6Salus University, Elkins Park, PA, USACorrespondence: Andrea Gibson, Oyster Point Pharma, Inc, 202 Carnegie Center, Suite 109, Princeton, NJ, 08540, USA, Tel +1-860-227-1034, Fax +1-856-433-8439, Email agibson@oysterpointrx.comPurpose: To evaluate OC-01 [varenicline solution nasal spray (VNS)] tear production and symptom outcomes in patients with dry eye disease by age, gender, race, ethnicity, and artificial tear use status.Patients and Methods: Adults ≥ 22 years of age diagnosed with dry eye disease, with Ocular Surface Disease Index score ≥ 23, corneal fluorescein staining score ≥ 2 in ≥ 1 region or ≥ 4 for all regions, and baseline Schirmer Test Score (STS) ≤ 10 mm, with no restrictions on eye dryness score (EDS). Efficacy was assessed using integrated data from ONSET-1 and ONSET-2 [vehicle control (VC), n=294; OC-01 VNS 0.03 mg, n=308]. Subgroups included age (≤ 55, 56− 65, > 65 years), gender (male, female), race (White, Black or African American), ethnicity (Hispanic or Latino, Not Hispanic or Latino), and artificial tear use (yes, no). Analysis of covariance models, with the covariates treatment, study site, and baseline severity measures, were used to calculate treatment−VC differences. Consistency of effect among subgroups was evaluated by conducting interaction tests.Results: Consistency of treatment effect across subgroups was observed for all endpoints, with P value for all treatment−subgroup interaction terms > 0.05. For % of patients with ≥ 10mm improvement in STS and least squares (LS) mean change from baseline in STS and EDS, there was improvement in tear production across demographic group categories. Artificial tear use did not change STS or EDS outcomes with OC-01 VNS.Conclusion: OC-01 VNS improved tear production and patient-reported symptom outcomes across a broad range of patients by age, gender, race, and ethnicity, and regardless of artificial tear use status at baseline. OC-01 VNS demonstrated a consistent benefit across an extensive range of patients with dry eye disease.Keywords: bioactivation, dry eye disease, nicotinic acetylcholine receptor, tear production, varenicline nasal spray

Purpose: To report on the management and effectiveness of treating patients with stage I Neurotrophic Keratitis using an 8-week course of topical recombinant human nerve growth factor (rhNGF, cenegermin). Observations: In this retrospective case series, punctate epithelial erosions (PEE), best corrected visual acuity (BCVA) and corneal sensation were followed and documented from 2 to 12 months in patients treated as per the standard of care. Clinical outcomes including changes in PEEs, corneal sensation and BCVA are reported. Most patients also had preexisting thyroid disease. Conclusions: All patients had clinically significant improvements in PEE, and corneal sensation. Three of the four patients had a significant improvement in BCVA, one patient had no change in their pre-treatment visual acuity (BCVA 20/20) The four patients studied also reported decreased photophobia and improvements in their quality of life. This case series provides real-world evidence of the safety and efficacy of cenegermin treatment of stage I NK for all four patients.

Purpose: To evaluate the rotational stability and visual performance of the enVista toric intraocular lens (IOL) (MX60ET) in cataract patients with pre-existing astigmatism., Setting: 6 US sites., Design: Prospective, multicenter., Methods: Cataract patients ≥18 years with pre-existing astigmatism (0.77 D to 4.53 D) underwent phacoemulsification and implantation of enVista toric IOL (MX60ET). Outcome measures were the proportion of patients with absolute IOL axis rotation of ≤5°, uncorrected and corrected distance visual acuities (UDVA and CDVA) at 4 m, uncorrected intermediate visual acuity (UIVA) at 66 cm, manifest refraction, and adverse events (AEs). The patients were followed up on Days 1-2, 7-14, 30-60, and 120-180., Results: Mean astigmatism of 101 eyes (101 subjects) reduced from 1.47 ± 0.64 D preoperatively to 0.38 ± 0.38 D at Days 120-180 (p <0.001) with 88.1% (N=89/101) of eyes achieving astigmatism within 0.75 D. Mean postoperative UDVA and UIVA were 0.10 ± 0.16 and 0.25 ± 0.15 logMAR respectively. While 79.2% (N=80/101) of patients had postoperative UDVA of 20/32 or better, 63.9% (N=62/97) had UIVA of 20/40 or better. The mean toric IOL rotation from the operative visit to Days 30-60 was 1.97 ± 2.06° with 97.4% (N=74/76) of eyes showing toric IOL rotation of 5˚ or less., Conclusion: The enhanced enVista toric IOL (MX60ET) demonstrated excellent rotational stability and astigmatic outcomes indicating good efficacy of the IOL for the correction of astigmatism during cataract surgery., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of ASCRS and ESCRS.)